Shares of Biomea Fusion surged 22.3% to $1.68 after the micro-cap biotech announced it finished enrolling patients in a key mid-stage trial of its experimental diabetes pill — a milestone that starts the clock on make-or-break data, but does nothing to solve the company's looming cash crunch.
Sixty-Four Patients Now Hold the Company's Future
Biomea said August 24 it completed enrollment in its randomized, double-blinded, placebo-controlled Phase II trial testing icovamenib — an oral drug designed to help the body restore its own insulin production — in type 2 diabetes patients whose blood sugar remains uncontrolled. Topline results on the 26-week primary endpoint are expected in the first quarter of 2027. With just 64 participants across 18 sites, this is a small trial. Positive data could validate an entirely new approach to diabetes; a miss could be fatal for a company with no revenue and no approved products.
A Second Trial and an Obesity Bet Widen the Target
A separate Phase II trial targeting type 2 diabetes patients failing on GLP-1 drugs — the blockbuster class led by Ozempic — is expected to complete enrollment before year end , with data anticipated in the second quarter of 2027.
Biomea is also running a Phase I obesity trial with initial weight-loss data due in Q3 2026, and has partnered with the University of Leicester to study icovamenib combined with semaglutide for obesity. Multiple shots on goal matter for a company this small, but each costs money it barely has.
$35 Million in Cash and a Going-Concern Warning
As of June 30, Biomea held just $35.2 million in cash, with its runway projected only into the second quarter of 2027.
The company itself states there is substantial doubt about its ability to continue as a going concern without additional financing.
Shares outstanding have already increased 44.65% in one year from prior dilutive offerings. Investor discussions have flagged recent warrant issuances and minimal reserves, with potential equity raises looming. Translation: the company will almost certainly need to sell more stock before that crucial Q1 2027 data readout, diluting existing shareholders further.
A Short Squeeze Tailwind Meets Analyst Optimism
Roughly 14.09 million shares — 19.5% of all outstanding stock — have been sold short , meaning today's jump likely forced some bearish traders to cover. Wall Street's median price target sits at $6.50, with a high of $16.00 and a low of $4.00 — all well above today's price, reflecting a bet that the science works. But at $1.68, this stock is a pure binary wager: either icovamenib's data in early 2027 rewrites the story, or the cash runs out first.